Update: Immunsuppression bei Organtransplantationen

Um eine Transplantatabstoßung zu vermeiden, ist nach Organtransplantation eine Immunsuppression unumgänglich – jedoch mit teils erheblichen Nebenwirkungen. Eine Kombinationstherapie kann die Nebenwirkungen begrenzen, ohne das Transplantat zu gefährden.

• Literatur

• 1 Houben P, Gotthardt DN, Radeleff B et al. Complication management after liver transplantation: Increasing patient safety by standardized approach and interdisciplinary cooperation. Chirurg 2015; PMID: 25604306
• 2 Starzl TE, Groth CG, Brettschneider L et al. Orthotopic homotransplantation of the human liver. Ann Surg 1968; 168: 392-415
• 3 Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005; 18: 511-519
• 4 Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58: 452-463
• 5 Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int 2013; 26: 673-683
• 6 Mangus RS, Fridell JA, Vianna RM et al. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786-795
• 7 Gotthardt DN, Bruns H, Weiss KH et al. Current strategies for immunosuppression following liver transplantation. Langenbeckʼs Arch Surg 2014; 399: 981-988
• 8 Préville X, Flacher M, LeMauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460
• 9 Xing T, Huang L, Yu Z et al. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 2013; 8: e71251
• 10 Verna EC, Farrand ED, Elnaggar AS et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplant 2011; 91: 1254-1260
• 11 Ramirez CB, Doria C, Frank AM et al. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 2013; 27: 463-471
• 12 De Simone P, Nevens F, De Carlis L et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020
• 13 Saliba F, De Simone P, Nevens F et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745
• 14 Fischer L, Klempnauer J, Beckebaum S et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation (PROTECT). Am J Transplant 2012; 12: 1855-1865
• 15 Sterneck M, Kaiser GM, Heyne N et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14: 701-710
• 16 Rodriguez-Peralvarez M, Manousou P, Lerut J et al. How much immunosuppression is needed after liver transplantation?. Clin Transplant 2014; 28: 6-7
• 17 Kidney Disease : Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J of Transplant 2009; 9 (Suppl. 03) S1-S155
• 18 Préville X, Flacher M, LeMauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460
• 19 Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465
• 20 Tydén G, Ekberg H, Tufveson G et al. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012; 94: e21
• 21 Morath C, Süsal C. Transplantation: rituximab induction only for sensitized kidney recipients?. Nat Rev Nephrol 2013; 9: 703-705
• 22 Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166
• 23 Wiland AM, Fink JC, Weir MR et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004; 77: 422
• 24 Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967
• 25 Hardinger KL, Brennan DC, Schnitzler MA. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. Transplantation 2009; 87: 1372
• 26 Miller JT, Collins CD, Stuckey LJ et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009; 29: 1166
• 27 Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9: 409
• 28 Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810
• 29 Atkison P, Joubert G, Barron A et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345: 894
• 30 Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38 (Suppl. 06) S25
• 31 Ekberg H, Tedesco-Silva H et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
• 32 Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535
• 33 Masson P, Henderson L, Chapman JR et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014;
• 34 Pascual J, Zamora J, Galeano C et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009;
• 35 Montero N, Webster AC, Royuela A et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev 2014;
• 36 Webb NJ, Douglas SE, Rajai A et al. Corticosteroid-Free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. Transplantation 2014; 99: 1178-1185
• 37 Woodside KJ, Schirm ZW, Noon KA et al. Fever, infection, and rejection after kidney transplant failure. Transplantation 2014; 97: 648-653
• 38 Augustine JJ, Woodside KJ, Padiyar A et al. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94: 738-743
• 39 Del Bello A, Congy-Jolivet N, Sallusto F et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7: 1310
• 40 Shapiro R, Carroll PB, Tzakis AG et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49: 1011
• 41 Ratcliffe PJ, Dudley CR, Higgins RM et al. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643
• 42 Andrews PAStandards Committee of the British Transplantation Society. Summary of the British Transplantation Society Guidelines for management of the failing kidney transplant. Transplantation 2014; 98: 1130
• 43 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. 2015 Im Internet: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015/report/1